On the public citation graph

Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity

0 signed · 12 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1056/nejmoa1205127openalex-snapshot

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

inferredcites →https://doi.org/10.1182/blood.v106.11.4856.4856openalex-snapshot

Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid.

inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.7012openalex-snapshot

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).

inferredcites →https://doi.org/10.2147/ott.s36980openalex-snapshot

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3777190openalex-extracted

Relative Risk of Hepatotoxicity Associated With BCR-ABL Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.20165openalex-snapshot

Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia

inferred← citeshttps://doi.org/10.1007/978-3-031-90598-8_18openalex-snapshot

Ponatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Efficacy, Mechanisms, and Cardiotoxic Challenges

inferred← citeshttps://doi.org/10.1007/s40278-019-64104-2openalex-snapshot

Ponatinib

inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.188949openalex-snapshot

Ponatinib: An update on its drug targets, therapeutic potential and safety

inferred← citeshttps://doi.org/10.1016/j.path.2023.04.006openalex-snapshot

Liver Pathology Related to Onco-Therapeutic Agents

inferred← citeshttps://doi.org/10.1016/j.toxlet.2024.08.007openalex-snapshot

Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity

inferred← citeshttps://doi.org/10.1080/14740338.2025.2460449openalex-snapshot

Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.